Genenta Science assumed with a Buy at Roth MKM

Roth MKM analyst Kumaraguru Raja assumed coverage of Genenta Science with a Buy rating and $15 price target. The company’s technology utilizes the tumor homing ability of naturally occurring proangiogenic Tie-2 monocytes to deliver a cytokine interferon-alpha precisely to tumors, and its Temferon Phase 1/2 trial in glioblastoma is ongoing, yielding promising initial data, the analyst tells investors in a research note. Roth MKM adds that it sees a “significant potential” for Genenta platform as the pipeline advances.